3
Announcements
Trials
Browse
Landscape
Status
Completed
9
Terminated
2
Active not recruiting
2
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
5
Multiple Myeloma
3
Uveal Melanoma
2
Melanoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Muscle Neoplasms
1
Leukemia, Plasma Cell
1
Chronic Pain
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Exercise
8
Standard of Care
5
trametinib
3
tislelizumab
3
Radiotherapy
3
Radiosurgery
3
Palliative Care
3
Paclitaxel
3
Gemcitabine
3
130-nm albumin-bound paclitaxel
3
trastuzumab deruxtecan
2
cemiplimab
2
Therapeutics
2
Surveys and Questionnaires
2
Resistance Training
2
Oxaliplatin
2
Nivolumab
2
Maintenance
2
Immune Checkpoint Inhibitors
2
Drug Therapy
2
Cisplatin
2
Carboplatin
2
vedolizumab
1
toripalimab
1
surufatinib
1
sparsentan
1
sintilimab
1
semaglutide
1
posaconazole
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasms
×
Melphalan
×
Clear all
NCT06154590
2023-12-04
NASBP-B-09
Paradyne Networks A Foundation
Not yet recruiting
100 enrolled